Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, UCL Division of Surgical and Interventional Science, London, UK.
Barts Cancer Institute, Queen Mary University of London, London, UK.
Eur Urol Oncol. 2021 Jun;4(3):473-482. doi: 10.1016/j.euo.2020.09.005. Epub 2020 Oct 24.
Current follow-up strategies for patients with renal cell carcinoma (RCC) after curative surgery rely mainly on risk models and the treatment delivered, regardless of the histological subtype.
To determine the impact of RCC histological subtype on recurrence and to examine the incidence, pattern, and timing of recurrences to improve follow-up recommendations.
DESIGN, SETTING, AND PARTICIPANTS: This study included consecutive patients treated surgically with curative intention (ie, radical and partial nephrectomy) for nonmetastatic RCC (cT1-4, M0) between January 2006 and December 2011 across 15 centres from 10 countries, as part of the euRopEan association of urology renal cell carcinoma guidelines panel Collaborative multicenter consortium for the studies of follow-Up and recurrence patterns in Radically treated renal cell carcinoma patients (RECUR) database project.
The impact of histological subtype (ie, clear cell RCC [ccRCC], papillary RCC [pRCC], and chromophobe RCC [chRCC]) on recurrence-free survival (RFS) was assessed via univariate and multivariate analyses, adjusting for potential interactions with important variables (stage, grade, risk score, etc.) Patterns of recurrence for all histological subtypes were compared according to recurrence site and risk criteria.
Of the 3331 patients, 62.2% underwent radical nephrectomy and 37.8% partial nephrectomy. A total of 2565 patients (77.0%) had ccRCC, 535 (16.1%) had pRCC, and 231 (6.9%) had chRCC. The median postoperative follow-up period was 61.7 (interquartile range: 47-83) mo. Patients with ccRCC had significantly poorer 5-yr RFS than patients with pRCC and chRCC (78% vs 86% vs 91%, p = 0.001). The most common sites of recurrence for ccRCC were the lung and bone. Intermediate-/high-risk pRCC patients had an increased rate of lymphatic recurrence, both mediastinal and retroperitoneal, while recurrence in chRCC was rare (8.2%), associated with higher stage and positive margins, and predominantly in the liver and bone. Limitations include the retrospective nature of the study.
The main histological subtypes of RCC exhibit a distinct pattern and dynamics of recurrence. Results suggest that intermediate- to high-risk pRCC may benefit from cross-sectional abdominal imaging every 6 mo until 2 yr after surgery, while routine imaging might be abandoned for chRCC except for abdominal computed tomography in patients with advanced tumour stage or positive margins.
In this analysis of a large database from 15 countries around Europe, we found that the main histological subtypes of renal cell carcinoma have a distinct pattern and dynamics of recurrence. Patients should be followed differently according to subtype and risk score.
目前,肾细胞癌(RCC)患者根治性手术后的随访策略主要依赖于风险模型和治疗方法,而不考虑组织学亚型。
确定 RCC 组织学亚型对复发的影响,并检查复发的发生率、模式和时间,以改进随访建议。
设计、设置和参与者:本研究纳入了 2006 年 1 月至 2011 年 12 月期间,来自欧洲 10 个国家的 15 个中心的连续接受根治性手术(即根治性和部分肾切除术)治疗的非转移性 RCC(cT1-4,M0)患者,作为欧洲泌尿外科协会肾细胞癌指南小组协作多国研究随访和复发性肾细胞癌患者(RECUR)数据库项目的一部分。
通过单变量和多变量分析评估组织学亚型(即透明细胞 RCC [ccRCC]、乳头状 RCC [pRCC]和嫌色细胞 RCC [chRCC])对无复发生存率(RFS)的影响,并调整了与重要变量(分期、分级、风险评分等)的潜在相互作用。根据复发部位和风险标准比较了所有组织学亚型的复发模式。
在 3331 例患者中,62.2%行根治性肾切除术,37.8%行部分肾切除术。共有 2565 例(77.0%)患者为 ccRCC,535 例(16.1%)为 pRCC,231 例(6.9%)为 chRCC。中位术后随访时间为 61.7(四分位距:47-83)个月。ccRCC 患者的 5 年 RFS 明显低于 pRCC 和 chRCC 患者(78%比 86%比 91%,p=0.001)。ccRCC 最常见的复发部位是肺和骨。中高危 pRCC 患者有更高的淋巴结复发率,包括纵隔和腹膜后淋巴结,而 chRCC 的复发罕见(8.2%),与较高的分期和阳性切缘有关,主要发生在肝脏和骨骼。局限性包括研究的回顾性。
RCC 的主要组织学亚型表现出不同的复发模式和动态。结果表明,中高危 pRCC 可能受益于术后 2 年内每 6 个月进行一次横断面腹部成像,而对于分期较高或切缘阳性的患者,除了腹部计算机断层扫描外,可能不需要对 chRCC 进行常规成像。
在这项来自欧洲 15 个国家的大型数据库的分析中,我们发现肾细胞癌的主要组织学亚型具有不同的复发模式和动态。应根据亚型和风险评分对患者进行不同的随访。